{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:28:21Z","timestamp":1768314501736,"version":"3.49.0"},"reference-count":10,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2023,12,22]]},"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1136\/jmg-2023-109818","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T13:45:43Z","timestamp":1711547143000},"page":"531-533","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study\u2014determination of immunogenicity"],"prefix":"10.1136","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8409-2886","authenticated-orcid":false,"given":"Malte","family":"Lenders","sequence":"first","affiliation":[{"name":"Internal Medicine D, Department of Nephrology, Hypertension and Rheumatology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[{"name":"Internal Medicine D, Department of Nephrology, Hypertension and Rheumatology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"key":"2025101710451408000_61.6.531.1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s13023-023-02937-6","article-title":"Safety and efficacy of Pegunigalsidase Alfa in patients with Fabry disease who were previously treated with Agalsidase Alfa: results from BRIDGE, a phase 3 open-label study","volume":"18","author":"Linhart","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"2025101710451408000_61.6.531.2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg-2023-109445"},{"key":"2025101710451408000_61.6.531.3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.omtm.2022.07.009","article-title":"Pre-existing anti-drug antibodies in Fabry disease show less affinity for Pegunigalsidase Alfa","volume":"26","author":"Lenders","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025101710451408000_61.6.531.4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1266082","article-title":"Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry disease","volume":"14","author":"Lenders","year":"2023","journal-title":"Front Immunol"},{"key":"2025101710451408000_61.6.531.5","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.omtm.2022.10.007","article-title":"Antibodies against recombinant enzyme in the treatment of Fabry disease: now you see them, now you don't","volume":"27","author":"van der Veen","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025101710451408000_61.6.531.6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","article-title":"Characterization of a chemically modified plant cell culture expressed human \u0391-Galactosidase-A enzyme for treatment of Fabry disease","volume":"114","author":"Kizhner","year":"2015","journal-title":"Mol Genet Metab"},{"key":"2025101710451408000_61.6.531.7","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12080","article-title":"Pegunigalsidase Alfa, a novel pegylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year phase 1\/2 clinical trial","volume":"42","author":"Schiffmann","year":"2019","journal-title":"J Inherit Metab Dis"},{"key":"2025101710451408000_61.6.531.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2018.11.008"},{"key":"2025101710451408000_61.6.531.9","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-Cov-2 lipid nanoparticle mRNA vaccine","volume":"16","author":"Ju","year":"2022","journal-title":"ACS Nano"},{"key":"2025101710451408000_61.6.531.10","doi-asserted-by":"crossref","first-page":"114079","DOI":"10.1016\/j.addr.2021.114079","article-title":"To Pegylate or not to Pegylate: immunological properties of Nanomedicine\u2019s most popular component, polyethylene glycol and its alternatives","volume":"180","author":"Shi","year":"2022","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmg-2023-109818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T17:45:23Z","timestamp":1760723123000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmg-2023-109818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,21]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/jmg-2023-109818"],"URL":"https:\/\/doi.org\/10.1136\/jmg-2023-109818","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]}}}